Merger creates ‘Urgo Medical North America’

URGO Medical, a global leader in wound care, has a majority stake in its partnership with SteadMed Medical as they merge their North American medical activities to form Urgo Medical North America, operating in the US and Canada for the moment. The new company will focus on specifically adapted dressings and treatment protocols for different types of acute and chronic wounds like diabetic foot ulcers, venous leg ulcers, pressure ulcers or burns. The product portfolio will include SteadMed Medical products Vashe and Drawtex and URGO Medical’s Restore Triact line.
Pierre Moustial, Urgo Group chief executive said: “Setting foot in the USA represents both a key milestone for our development and a strategic priority. We are happy to enter this new market with our partner SteadMed, who also has a strong expertise in advanced wound care and who will help us to develop innovative solutions to assist healthcare professionals in reducing healing time. Our two companies share the same values: a history of entrepreneurship and the long term vision of a family business.”
SteadMed Medical commercializes advanced wound care products for optimizing wound bed preparation. SteadMed’s chairman and CEO at the newly formed Urgo Medical North America, Michael Steadman, said: “This new partnership with URGO is a great opportunity for us to enhance our growth in North America and to launch together new innovative products in advanced wound care, for patients who suffer from wounds associated with diabetes, blood circulation problems, infection and other wound healing complications.”